Literature DB >> 10049146

Volatile anesthetics and a volatile convulsant differentially affect GABA(A) receptor-chloride channel complex.

Y Ikemoto1, M Yamashita, T Yano.   

Abstract

1. General anesthetics at clinical concentrations are known to affect neurotransmitter-gated ion channels in postsynaptic membranes. 2. Volatile anesthetics suppress excitatory transmissions, whereas they potentiate inhibitory chloride currents evoked by GABA or glycine. Hexafluorodiethyl ether (a volatile convulsant) markedly depresses the GABA(A) response but not the glycine-evoked chloride current or the glutamate-induced excitatory response. 3. Molecular biology has revealed that GABA(A) receptor is a heteromeric pentamer composed of alpha, beta, gamma, delta, and/or rho subunits. In baculovirus-Sf9 expression system, the gamma subunit was crucial for potentiation of the GABA-induced chloride current by volatile anesthetics. 4. Following sustained presence of GABA and high concentrations of isoflurane, simultaneous washout of both agents evoked a slowly decaying surge current, whose nature is controversial.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10049146     DOI: 10.1016/s0378-4274(98)00189-1

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  3 in total

Review 1.  General anaesthetic actions on ligand-gated ion channels.

Authors:  M D Krasowski; N L Harrison
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

2.  Effects of Volatile Anaesthetics and Iron Dextran on Chronic Inflammation and Antioxidant Defense System in Rats.

Authors:  Dyana Odeh; Nada Oršolić; Emanuela Adrović; Lydia Gaćina; Petra Perić; Sahar Odeh; Vedran Balta; Nikola Lesar; Marina Kukolj
Journal:  Antioxidants (Basel)       Date:  2022-04-03

3.  A pharmacodynamic model of respiratory rate and end-tidal carbon dioxide values during anesthesia in children.

Authors:  Ji-Hyun Lee; Pyo-Yoon Kang; Young-Eun Jang; Eun-Hee Kim; Jin-Tae Kim; Hee-Soo Kim
Journal:  Acta Pharmacol Sin       Date:  2018-08-30       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.